From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Subcutaneous Unfractionated vs. Low-Molecular-Weight Heparin in Venous Thromboembolism

Weight-adjusted dosing of subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin.

During the past decade, therapy for venous thromboembolism (VTE) has shifted from intravenous unfractionated heparin to subcutaneous low-molecular-weight heparin (LMWH), which does not require laboratory monitoring and can be given in outpatient settings. However, a few previous studies have suggested that weight-adjusted subcutaneous unfractionated heparin may also be effective.

In this open-label, but rater-blinded, trial in Canada and New Zealand, researchers randomized 708 adults with VTE to one of two treatments — weight-adjusted subcutaneous unfractionated heparin without APTT monitoring (initial dose 333 U/kg, followed by 250 U/kg every 12 hours) or LMWH (100 IU/kg every 12 hours). These treatments were continued for at least 5 days and until warfarin therapy had achieved an INR of 2.0 or higher. Eighty-one percent of patients had deep venous thrombosis alone, and 19% had symptomatic pulmonary embolism.

There was no significant difference between groups in rates of recurrent VTE at 3 months (about 3.5%) or in major bleeding complications at 10 days (about 1%). Approximately 70% of both groups were treated entirely on an outpatient basis.

Comment: These findings indicate that weight-adjusted unfractionated heparin — administered subcutaneously and without APTT monitoring — is as safe and effective as LMWH, at far lower cost (US$40 vs. $700 for medication). Nevertheless, an editorialist calls for a fully blinded replication of the data before the approach can be recommended clinically.

— Thomas L. Schwenk, MD

Published in Journal Watch General Medicine September 21, 2006

Citation(s):

Kearon C et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006 Aug 23/30; 296:935-42.

Carson JL. Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: Issues of efficacy and cost. JAMA 2006 Aug 23/30; 296:991-3.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Other Perspectives

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2006. Massachusetts Medical Society. All rights reserved.